[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universidad Complutense de Madrid\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":708},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,46,0,25,[9,49,83,110,139,166,185,199,223,250,269,305,338,367,397,427,448,477,511,535,561,581,624,650,682],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100567639","effect-of-a-probiotic-formula-in-mild-cognitive-impairement-100567639",false,"NCT06670807","Effect of a Probiotic Formula in Mild Cognitive Impairement","Clinical Trial to Evaluate the Efficacy of a Probiotic Formula on Cognitive Function in Mild Cognitive Impairement Patients.","PROBIOMIND","Inclusion Criteria:\n\n* Men and women aged between 60 and 85 years.\n* Present \"Mild Cognitive Impairment\" (MCI) based on:\n* MoCA test (\\\u003C 26 points) or score adjusted for educational level\n* and CDR test (≤ 0.5 points)\n* Maintain functional capacity according to the (I)ADL test (≥ 70 points)\n* Show \"cognitive concern\" reported by the participant and\u002For a surrogate caregiver\n* Demonstrate longitudinal decline in cognitive function (progressive and not stabilized) for more than 3-5 years.\n* BMI ≥ 20 and \\\u003C 30 kg\u002Fm²\n* Absence of a family or social environment that prevents treatment adherence.\n* Adequate cultural level and understanding of the clinical study.\n* Agree to participate voluntarily in the study and provide written informed consent.\n\nExclusion Criteria:\n\n* Subjects with severe neurological or psychiatric disorders due to any of the following causes: severe dementia, depression, epilepsy, schizophrenia, or bipolar disorder.\n* Subjects who have suffered a severe stroke prior to the study (FAZKAS=3)\n* Subjects with a history of malignancy \\\u003C 5 years (\\\u003C 5 years if the brain was affected)\n* Subjects who have experienced severe traumatic brain injury with structural brain injury and\u002For prior brain surgery\n* Subjects with pacemakers and those with metal implants that may interfere with EEG or MRI\n* Subjects treated with medications: benzodiazepines, neuroleptics, narcotics, anticonvulsants, or sedative-hypnotics in the last 3 months\n* Subjects who have been treated with antibiotics or probiotic supplements at least 3 months before the start of the study.\n* Subjects with hearing or visual impairments that prevent the evaluations included in the study\n* Subjects with severe illnesses affecting nutritional status (liver, kidney, etc.)\n* Subjects who have engaged in weight loss diets or significant dietary changes in the 8 weeks prior to starting the study\n* Subjects with high alcohol consumption (\\> 3 alcoholic beverages per day)","ALL","65 Years","85 Years",{"count":22,"type":23},100,"ESTIMATED","INTERVENTIONAL",[26],"NA","Mild cognitive impairment is currently one of the most relevant social challenges, as its prevalence is expected to increase and it is associated with a higher risk of developing Alzheimer's disease or other types of dementia. Therefore, it is necessary to seek strategies that can be applied in the early stages to delay or reverse the progression of the disease.\n\nIn this context, probiotics have emerged as a promising alternative for managing cognitive disorders. This project is a clinical-nutritional trial to evaluate the utility of consuming a dietary supplement containing probiotics on the cognitive function of individuals with mild cognitive impairment. The study will involve 100 participants, selected from the Geriatrics Unit of San Carlos Clinical Hospital, as well as through various Leisure Centers in Madrid, randomly assigned to two groups of 50 individuals each (Experimental Group and Control Group). Participants assigned to the experimental group will consume the dietary supplement, while those in the control group will receive a placebo, which is a product without probiotics. Both groups will take 1 capsule per day of the assigned product at breakfast for 16 weeks. During this time, changes will be analyzed in various imaging tests, cognitive tests, and some blood parameters related to cognitive function. Changes in gut microbiota and different lifestyle factors (diet, body composition, physical activity, sleep) will also be evaluated.",[29],"Mild Cognitive Impairment (MCI)",[29,31,32,33,34,35],"Probiotic","Cognitive function","Microbiota","Nutrition","Elderly","RECRUITING","2026-07-14",{"date":39,"type":40},"2026-07-16","ACTUAL",{"date":42,"type":40},"2026-03-21",{"date":44,"type":23},"2027-06",{"name":46,"class":47},"Universidad Complutense de Madrid","OTHER",2,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":24,"phases":60,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":4},"100646439","bio-descaling-toothpaste-for-dental-calculus-reduction-100646439","NCT07689071","Bio-Descaling Toothpaste for Dental Calculus Reduction","Efficacy of a Novel Toothpaste Containing a Bio-Descaling Powder (BDP) in Reducing Dental Calculus: A Double Blind Randomized Controlled Clinical Trial","AntiCal","Inclusion Criteria:\n\nPatients with a healthy but reduced periodontium undergoing a supportive periodontal care (SPC) program and\u002For patients with biofilm induced gingivitis, fulfilling the following criteria:\n\n1. Aged 18 years and older;\n2. Systemically healthy, following the criteria of American Society of Anesthesiology (ASA), type I or II;\n3. Having at least 10 opposing teeth units with presence of at least three natural lower anterior teeth;\n4. Presenting at least 1.5 mm of calculus width on the lingual surface of at least one mandibular anterior teeth (Volpe-Manhold index of at least 1.5 in the lingual side of at least one of the lower anterior teeth) ;\n5. For patients in SPC, for at least 6 months, and the last tooth cleaning at least 3 months before, fulfilling the end point criteria of periodontal therapy \\[no pockets ≥ 6 mm or \\> 4 mm with bleeding on probing (BOP)\\] . Localized pockets of 6 mm, without bleeding on probing, are allowed, except in the anterior-inferior sextant.\n6. Agree to follow the study instructions, including adherence to study arm treatment, for the study timeline.\n\nExclusion Criteria:\n\nSubjects will be excluded from participating in the study if:\n\n1. Pregnancy: pregnant women at high risk of developing gum inflammation that usually occurs during pregnancy, which could introduce bias to the study;\n2. Any physical handicap, psychological or health conditions that might jeopardize the ability of the patient to brush his\u002F her teeth, these complications may cause bias in the study. Smokers of 10 or more cigarettes per day will be excluded (Dietrich, Bernimoulin, \\& Glynn, 2004);\n3. Antibiotics or anti-inflammatory drugs taken within 1 month prior to the study, to avoid bias when assessing the gum health;\n4. Currently using chlorhexidine or other antiseptic products, since these products can affect biofilm and calculus formation, therefore they can introduce bias in the assessment of calculus removal by our toothpaste;\n5. Sensitivity to tartar-control toothpastes;\n6. Unable to return for evaluations\u002Fstudy recalls, to avoid the significant loss in the number of participants.",true,"18 Years",{"count":22,"type":23},[26],"Dental calculus is a calcified mineralized plaque composed primarily of calcium phosphate salts covered by an unmineralized bacterial biofilm layer. It provides a substrate for bacterial colonization and soft biofilm retention, promoting the growth of pathogenic plaque, further calculus formation, gingival tissue inflammation, that could progress to periodontitis and tooth loss. Therefore, removal of dental calculus and prevention of its formation are important for maintaining periodontal health.\n\nProfessional mechanical removal remains the most effective approach to control existing dental calculus; however, it is labor-intensive and represents a burden for patients in terms of costs and access to oral health professionals. Several toothpastes have been developed to dissolve and soften mineralized deposits using abrasive and\u002For chemical agents. Nevertheless, highly abrasive formulations may damage tooth structures and only reduce approximately 30-50% of dental calculus, while dentifrices containing mineralization and crystallization inhibitors can prevent calculus formation but are unable to remove already formed deposits.\n\nTo address these limitations, a Bio-Descaling Powder (BDP) toothpaste has recently been introduced with the aim of removing existing dental calculus. Preliminary clinical evidence showed that the amount of calculus removed with D-Tart toothpaste was five times greater than that achieved with Colgate Total® toothpaste.\n\nGiven the high prevalence of periodontal diseases and the potential role of dental calculus in their initiation and progression, effective strategies for calculus removal and prevention are of considerable clinical interest. The use of an effective toothpaste could reduce the need for professional periodontal interventions or shorten treatment time, thereby decreasing costs and patient burden.\n\nThe aim of this study is to evaluate the efficacy of a Bio-Descaling Powder (BDP)-containing toothpaste, compared with a placebo toothpaste, in decreasing the presence of already formed dental calculus.",[63,64,65],"Dental Calculus","Gingivitis and Periodontal Diseases","Periodontal Diseases",[67,68,69,70,71,72,73],"dental calculus","calculus removal","Bio-descaling powder toothpaste","Periodontal Maintenance","Gingival inflammation","Supportive Periodontal Care","Periodontal diseases","NOT_YET_RECRUITING","2026-07-04",{"date":77,"type":40},"2026-07-08",{"date":79,"type":23},"2026-07",{"date":81,"type":23},"2027-01",{"name":46,"class":47},{"id":84,"slug":85,"hasResults":12,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":57,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":92,"conditions":93,"keywords":94,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":48},"100605841","longitudinal-follow-up-study-to-determine-the-predictive-ability-of-a-panel-of-biomarkers-in-saliva-in-healthy-and-periodontally-affected-patients-100605841","NCT07167771","LONGITUDINAL FOLLOW-UP STUDY TO DETERMINE THE PREDICTIVE ABILITY OF A PANEL OF BIOMARKERS IN SALIVA IN HEALTHY AND PERIODONTALLY AFFECTED PATIENTS","FLOE_long","Inclusion Criteria:\n\n* Participants from the cohort involved in the previous cross-sectional study (code 23\u002F481-E).\n* Adults (≥ 18-year-old)\n* Being able to sign an informed consent form\n* Willing to participate in this observational investigation\n* Diagnosed as periodontally healthy, gingivitis, treated periodontitis patient (stable \u002F unstable), periodontitis stages I \\& II, or periodontitis stages III and IV (Papapanou et al. 2023) in the previous cross-sectional study (code 23\u002F481-E)\n\nExclusion Criteria:\n\n* Patients fitting to all the above inclusion criteria will be excluded from the study if unable to attend to the study-related procedures.",{"count":22,"type":23},"OBSERVATIONAL","Objective: The main aim of this longitudinal clinical study is to evaluate the predictive ability of a panel of salivary biomarkers in determining periodontal health status in 2 years follow up in a group of healthy and periodontally affected individuals.\n\nMaterial and methods: In this longitudinal, observational follow-up study, patients previously enrolled in a cross-sectional study at the Periodontal Postgraduate Clinic, University Complutense of Madrid, will be re-evaluated over a 2-year period. Participants (≥18 years) will be categorized into diagnostic groups based on the 2018 classification of periodontal diseases, including periodontally healthy, gingivitis, treated periodontitis (stable\u002Funstable), and various stages of periodontitis. The study will include follow-up visits at 1 and 2 years. At each visit, participants will undergo a comprehensive medical examination to assess age, gender, weight, height, waist circumference, blood pressure, temperature, smoking and alcohol history, systemic health, and HbA1c levels. A periodontal examination will be performed at six sites per tooth, and clinical parameters including plaque, bleeding on probing, probing depth, recession, and tooth loss will be recorded. Saliva and subgingival plaque samples will be collected for biomarker and microbiological analysis. Salivary biomarkers will be measured using multiplex immunoassays, and bacterial quantification will be performed by multiplex qPCR. Data analyses: Descriptive statistics will be used to report the clinical variables and patients will be grouped according to the pre-established diagnostic categories (periodontally healthy, gingivitis, treated periodontitis patient. In order to determine the possible statistical relationship with the medical, biochemical and microbiological variables assessed, a crude bivariate analysis will first be performed by applying a mean comparison test for quantitative variables (ANOVA) and a proportion comparison test for categorical variables (Chi-square). Subsequently, those variables identified as relevant in the crude analyses will be included as confounding and\u002For interaction factors in a binary logistic regression model, considering the presence of periodontitis as a response variable, in order to obtain crude and adjusted OR values, together with their corresponding 95% CIs. Based on the results obtained in the biomarker analysis, a relevant statistical analysis will be performed, taking into account all the variables collected in the study. For periodontitis cases, treatment response over time will be analyzed, with subgroup comparisons between responders and non-responders.",[65],[95,96,97,98,99,100,101],"periodontal diseases","saliva","biomarkers","prediction","periodontopathogens","interleukin 1","MMP-8","2026-06-26",{"date":104,"type":40},"2026-06-29",{"date":106,"type":40},"2025-10-01",{"date":108,"type":23},"2028-10",{"name":46,"class":47},{"id":111,"slug":112,"hasResults":12,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":24,"phases":120,"briefSummary":121,"conditions":122,"keywords":124,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":138},"100643670","dry-needling-or-percutaneous-electrolysis-for-managing-myofascial-trigger-points-100643670","NCT07637760","Dry Needling or Percutaneous Electrolysis for Managing Myofascial Trigger Points?","Dry Needling or Percutaneous Electrolysis for Managing Myofascial Trigger Points? A Randomized Clinical Trial","PEDN","Inclusion Criteria:\n\n* Adults\n* Presence of shoulder pain for at least 3 months.\n* Shoulder pain intensity greater than 3 points on the visual analogue scale (VAS).\n* Shoulder-related disability greater than 20 points on the DASH questionnaire.\n* Presence of at least one active myofascial trigger point in the infraspinatus muscle.\n* Reproduction of the patient's familiar shoulder pain during palpation of the infraspinatus trigger point.\n* Ability to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Previous shoulder surgery or traumatic shoulder injury in the affected region.\n* Presence of severe structural or systemic pathology affecting the shoulder region, such as fracture, tumour, infection, inflammatory disease, or neurological disorder.\n* Clinical signs suggestive of cervical radiculopathy or other neurological conditions that could explain the shoulder symptoms.\n* Use of physiotherapy treatment, invasive therapy, or analgesic\u002Fanti-inflammatory medication during the week before participation.\n* Contraindications to dry needling or percutaneous electrolysis, including needle phobia, anticoagulant therapy, bleeding disorders, pregnancy, pacemaker or implanted electrical devices, local skin infection, or altered skin sensitivity in the treatment area.",{"count":119,"type":23},40,[26],"Dry needling (DN) and percutaneous electrolysis (PE) are minimally invasive physiotherapy techniques commonly used for the management of myofascial trigger points. DN consists of inserting a fine filiform needle into a hyperirritable area within a taut band of skeletal muscle, with the aim of eliciting local twitch responses and reducing myofascial pain. PE follows a similar needle-based approach but combines the mechanical stimulus of the needle with the application of a galvanic electrical current, producing an electrochemical reaction in the targeted tissue. Both techniques have been increasingly used in clinical practice for musculoskeletal pain conditions, including shoulder pain, although the evidence comparing their relative effectiveness remains limited.\n\nShoulder pain is one of the most prevalent musculoskeletal disorders and is frequently associated with the presence of active myofascial trigger points. Among the shoulder muscles, the infraspinatus has been identified as a clinically relevant structure because its trigger points may reproduce referred pain patterns commonly reported by patients with shoulder symptoms and may contribute to pain, reduced strength, altered mobility, and functional disability. Previous studies have suggested that invasive treatment of infraspinatus trigger points may produce short-term improvements in pain sensitivity and shoulder-related symptoms. However, most available research has examined dry needling or percutaneous electrolysis separately, and direct comparisons between both interventions in patients with shoulder pain remain scarce.\n\nThe physiological mechanisms underlying these techniques are not yet fully understood. Dry needling is thought to act through mechanical and neurophysiological mechanisms, including disruption of dysfunctional motor endplates, reduction of local nociceptive input, elicitation of local twitch responses, and activation of segmental and descending inhibitory pathways. Percutaneous electrolysis may share some of these needling-related effects, while also adding a galvanic current that may induce local biochemical changes and promote tissue recovery processes. Nevertheless, it remains unclear whether the addition of electrical current provides superior clinical effects compared with dry needling alone.\n\nSince limited research has directly compared dry needling and percutaneous electrolysis applied to active myofascial trigger points of the infraspinatus in patients with shoulder pain, the present study aimed to compare the effectiveness of both techniques as complementary interventions to manual therapy and therapeutic exercise. Specifically, this study sought to determine whether percutaneous electrolysis or dry needling produced greater short-term improvements in pain intensity and shoulder-related disability.",[123],"Shoulder Pain",[125,126,127,128,129],"Dry needling","Percutaneous electrolysis","Physiotherapy","Manual therapy","Exercise","2026-06-09",{"date":132,"type":40},"2026-06-10",{"date":134,"type":23},"2026-09-01",{"date":136,"type":23},"2027-02-01",{"name":46,"class":47},1,{"id":140,"slug":141,"hasResults":12,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":12,"sex":18,"minAge":147,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":24,"phases":150,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":163,"leadSponsor":165,"locationsCount":138},"100626313","efficacy-of-artificial-intelligence-assisted-therapeutic-exercise-in-patients-with-knee-osteoarthritis-100626313","NCT07434011","Efficacy of Artificial Intelligence-Assisted Therapeutic Exercise in Patients With Knee Osteoarthritis","Efficacy of Artificial Intelligence-Assisted Therapeutic Exercise in Patients With Knee Osteoarthritis: A Randomized Controlled Clinical Trial","ET-AIAR","Inclusion Criteria (based on National Institute for Health and Care Excellence (NICE) guidance):\n\n* Clinical criteria for KOA: age ≥45 years, activity-related knee pain, and morning knee stiffness lasting ≤30 minutes.\n* Knee pain for 3 months or longer.\n* Knee pain on most days during the previous month.\n* Overall knee pain intensity ≥4 on an 11-point Numerical Rating Scale (NRS; 0-10) during the previous week.\n* Ownership of a smartphone and ability to use a mobile application.\n* Internet access at home and\u002For via the mobile phone.\n* Ability to provide informed consent, participate, and complete study assessments.\n\nExclusion Criteria:\n\n* Having a planned knee arthroplasty (knee replacement) surgery.\n* Knee prosthesis\u002Farthroplasty in the most painful knee.\n* Participation in a therapeutic exercise program for knee osteoarthritis within the past 6 weeks.\n* Infiltration for knee osteoarthritis within the past 12 weeks.\n* Inflammatory arthritic conditions.\n* A fall in the past 12 months without medical clearance to perform unsupervised home exercise.\n* Being homebound during the past month without medical clearance to perform unsupervised home exercise.\n* Failing the pre-exercise screening and not having medical clearance to perform unsupervised home exercise.\n* Inability to communicate in Spanish.\n* Any neurological or systemic disease that may limit participation in the study.","45 Years",{"count":149,"type":23},84,[26],"Knee osteoarthritis is a common, chronic degenerative condition that causes pain, functional limitations, and reduced quality of life, especially in adults older than 50 years. Although clinical practice guidelines recommend therapeutic exercise and physical therapy as the first-line treatment, many patients do not receive or adhere to the recommended programs. Digital health tools may help expand access and improve adherence by supporting home-based exercise.\n\nThis study is a parallel-group, randomized controlled clinical trial designed to evaluate the effectiveness of an artificial intelligence (AI)-assisted therapeutic exercise program delivered through a web-based app compared with a conventional home exercise program provided on paper in adults with knee osteoarthritis. The primary goal is to determine whether the AI-assisted program produces greater improvements in pain and knee-related function. Secondary goals include assessing changes in health-related quality of life and patient-perceived overall improvement, and comparing implementation outcomes like adherence, usability, satisfaction, self-efficacy for exercise, and use of the prescribed exercise resource (paper vs web platform). Participants will be recruited from the Department of Physical Medicine and Rehabilitation at Hospital Universitario 12 de Octubre and randomly assigned to either the AI-assisted exercise group or the conventional exercise group. The AI-assisted web app will adjust exercise dose and progression based on participant-reported pain and perceived exertion, using decision rules informed by clinical practice guidelines and high-quality research evidence. Both groups will complete a 6-week home-based exercise program and will also attend weekly in-person group sessions that will be held separately by study arm (experimental and control groups will not mix) to reduce cross-contamination and support masking procedures. These sessions will be used to address questions, reinforce the protocol, and monitor for adverse events. Clinical outcomes will include pain intensity (visual analog scale), knee-related disability and function (WOMAC), health-related quality of life (EQ-5D), and patient global rating of change (GROC). Physical performance outcomes (30-second Chair Stand Test and Stair Climb Test) will be assessed at baseline and 1 week after completion of the 6-week intervention. Assessments will be conducted at baseline, one week after the 6-week intervention, and at 3 and 6 months after the intervention, with the exception of physical performance outcomes, which will be assessed at baseline and 1 week post-intervention.",[153],"Knee Osteoarthritis",[155,156,157,158],"osteoarthritis","knee","exercise","digital intervention","2026-05-13",{"date":161,"type":40},"2026-05-18",{"date":159,"type":40},{"date":164,"type":23},"2027-03-15",{"name":46,"class":47},{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":24,"phases":175,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":182,"leadSponsor":184,"locationsCount":138},"100621956","immediate-and-1-week-efficacy-of-a-single-session-of-sciatic-nerve-electrical-stimulation-in-the-management-of-low-back-related-leg-pain-100621956","NCT07377357","Immediate and 1-week Efficacy of a Single Session of Sciatic Nerve Electrical Stimulation in the Management of Low-back Related Leg Pain","Inclusion Criteria:\n\n* Neuropathic-like LBRLP (sciatica).\n* S-LANSS score ≥ 12 points.\n* LBRLP lasting more than 6 months.\n* Age between 18 and 70 years.\n* LBRLP in the past 4 weeks has been severe enough to limit usual activities or change daily routines for more than 1 day.\n* At least one period of 6 months to 1 year during which the participant did not go a full month without LBRLP.\n* LBRLP intensity of at least 3\u002F10 on the NPRS.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Acute injury or recent major trauma history.\n* Relevant painful conditions of the hip joint or pelvic\u002Fsacroiliac region.\n* Symptoms compatible with cauda equina syndrome (loss of bladder\u002Fbowel control, sexual dysfunction, paralysis of lower limbs, etc.).\n* Previous surgery on the spine, pelvis or hip.\n* Prior treatment with anesthetic or anti-inflammatory blocks or with radiofrequency (facet, sacroiliac, radicular, epidural, etc.) in the past two years.\n* Any neurological or systemic disease that could limit participation in the study.\n* Inability to communicate in Spanish or understand study instructions and content.\n* General contraindications for invasive physiotherapy and electrotherapy techniques.","70 Years",{"count":174,"type":23},88,[26],"This clinical study focuses on people who experience long-term low-back related leg pain (commonly called sciatica). This type of pain is often associated with nerve irritation or compression in the lower spine and can cause symptoms like shooting or burning pain, tingling, numbness, or weakness in the leg. Many patients continue to suffer from this problem for months or years, and available treatments (including painkillers, anti-inflammatory drugs, or even surgery) do not always provide lasting relief. Because of this, there is a strong need to explore safe, non-drug, non-surgical therapies. The purpose of this study is to test the immediate and short-term efficacy and safety of a single session of a treatment called Percutaneous Electrical Nerve Stimulation (PENS) when applied near the sciatic nerve, the large nerve that runs from the lower back through the buttock and down the leg. PENS uses very thin sterile needles inserted under ultrasound guidance next to the nerve. A gentle electrical current is then applied for about 30 minutes to stimulate the nerve in a controlled way. This may help calm down nerve sensitivity, reduce inflammation, and decrease pain. The investigators will compare PENS with three other options: Transcutaneous Electrical Nerve Stimulation (TENS): A commonly used therapy where mild electrical stimulation is applied through adhesive patches placed on the skin; Dry needling without electrical current: Thin needles are inserted under ultrasound guidance but no current is applied; and placebo treatment: A simulated version of the therapy with no active current, designed to look and feel similar so that participants do not know which treatment they are receiving. The study is designed as a randomized, controlled, double-blind trial, which means that participants are assigned to one of the four groups by chance (like flipping a coin), and neither the patients nor the therapists who collect the measurements will know which treatment has been given. This design ensures fairness and reliability of the results. The investigators will measure: Back and leg pain levels, using a simple 0-10 scale; Disability, meaning how much the pain limits daily activities, measured with a well-known questionnaire; Quality of life, both physical and mental health aspects; Nerve-related pain features, like burning or electric-like sensations; Flexibility and movement, through the Straight Leg Raise test; Sensitivity to pressure and nerve stiffness, using ultrasound elastography, which is a safe imaging technique; and patients' global impression of improvement and any side effects. Assessments will take place before and immediately after the treatment session and after 1 week, allowing the investigators to see both the immediate and short-term effects. Safety considerations: Previous research shows that PENS and similar techniques are generally very safe. The most common side effects are mild and short-lasting, including temporary soreness, heaviness in the leg, or a small bruise. Serious complications are extremely rare. To minimize risks, all procedures will be carried out by experienced physiotherapists, using real-time ultrasound to guide needle placement and ensure accuracy. Only sterile, single-use needles are employed. By comparing PENS, TENS, dry needling, and placebo, this study seeks to determine whether a single session of PENS provides superior benefits in reducing pain, improving function, and enhancing quality of life for patients with sciatica-type low back pain. If successful, this treatment could become a valuable alternative to drugs or surgery, offering patients a safe and effective therapy to better manage their condition and regain daily function.",[178],"Sciatica",{"date":180,"type":40},"2026-05-14",{"date":159,"type":40},{"date":183,"type":23},"2027-11",{"name":46,"class":47},{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":172,"enrollmentInfo":190,"targetDuration":4,"studyType":24,"phases":191,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":194,"startDateStruct":195,"completionDateStruct":196,"leadSponsor":198,"locationsCount":138},"100621683","efficacy-of-sciatic-nerve-electrical-stimulation-and-therapeutic-exercise-in-the-management-of-low-back-related-leg-pain-100621683","NCT07373808","Efficacy of Sciatic Nerve Electrical Stimulation and Therapeutic Exercise in the Management of Low-back Related Leg Pain",{"count":174,"type":23},[26],"This clinical study focuses on people who experience long-term low-back related leg pain (commonly called sciatica). This type of pain is often associated with nerve irritation or compression in the lower spine and can cause symptoms like shooting or burning pain, tingling, numbness, or weakness in the leg. Many patients continue to suffer from this problem for months or years, and available treatments (including painkillers, anti-inflammatory drugs, or even surgery) do not always provide lasting relief. Because of this, there is a strong need to explore safe, non-drug, non-surgical therapies. The purpose of this study is to test the efficacy and safety of a treatment called Percutaneous Electrical Nerve Stimulation (PENS) when applied near the sciatic nerve, the large nerve that runs from the lower back through the buttock and down the leg, in combination with a therapeutic exercise program. PENS uses very thin sterile needles inserted under ultrasound guidance next to the nerve. A gentle electrical current is then applied for about 30 minutes to stimulate the nerve in a controlled way. This may help calm down nerve sensitivity, reduce inflammation, and decrease pain. We will compare PENS with three other options: Transcutaneous Electrical Nerve Stimulation (TENS): A commonly used therapy where mild electrical stimulation is applied through adhesive patches placed on the skin; Dry needling without electrical current: Thin needles are inserted under ultrasound guidance but no current is applied; and placebo treatment: A simulated version of the therapy with no active current, designed to look and feel similar so that participants do not know which treatment they are receiving. In addition to these treatments, all participants will take part in a structured exercise program aimed at strengthening the lower back, pelvis, and legs. Exercises like curl-ups, planks, bridges, bird-dogs, and squats will be supervised weekly for six weeks, with guidance to continue practicing at home. Exercise is included because it is known to help improve mobility, strength, and recovery in people with back problems. The study is designed as a randomized, controlled, double-blind trial, which means that participants are assigned to one of the four groups by chance (like flipping a coin), and neither the patients nor the therapists who collect the measurements will know which treatment has been given. This design ensures fairness and reliability of the results. We will measure: Back and leg pain levels, using a simple 0-10 scale; Disability, meaning how much the pain limits daily activities, measured with a well-known questionnaire; Quality of life, both physical and mental health aspects; Nerve-related pain features, like burning or electric-like sensations; and patients' global impression of improvement and any side effects. Assessments will take place before starting the treatment, at the end of the 6-week program, and then again at 3 and 6 months. This allows us to see both the short-, mid- and long-term effects. Safety considerations: Previous research shows that PENS and similar techniques are generally very safe. The most common side effects are mild and short-lasting, including temporary soreness, heaviness in the leg, or a small bruise. Serious complications are extremely rare. To minimize risks, all procedures will be carried out by experienced physiotherapists, using real-time ultrasound to guide needle placement and ensure accuracy. Only sterile, single-use needles are employed. By comparing PENS, TENS, dry needling, and placebo, this study seeks to determine whether PENS in combination with therapeutic exercise provides superior benefits in reducing pain, improving function, and enhancing quality of life for patients with sciatica-type low back pain. If successful, this treatment could become a valuable alternative to drugs or surgery, offering patients a safe and effective therapy to better manage their condition and regain daily function.",[178],{"date":180,"type":40},{"date":159,"type":40},{"date":197,"type":23},"2027-12",{"name":46,"class":47},{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":19,"enrollmentInfo":206,"targetDuration":4,"studyType":24,"phases":208,"briefSummary":209,"conditions":210,"keywords":211,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":48},"100613694","impact-of-different-electrical-frequencies-used-in-percutaneous-neuromodulation-on-muscle-strength-and-pressure-pain-thresholds-100613694","NCT07269925","Impact of Different Electrical Frequencies Used in Percutaneous Neuromodulation on Muscle Strength and Pressure Pain Thresholds","PENS-DOSE","Inclusion Criteria:\n\n* Presence of at least one latent myofascial trigger point (MTrP) in the infraspinatus muscle, identified according to the most recent Delphi consensus criteria.\n* Ability to read, understand, and sign the written informed consent form.\n\nExclusion Criteria:\n\n* Current pharmacological treatment that may affect muscle tone.\n* History of shoulder or spinal surgery.\n* Traumatic disorders such as whiplash-associated injuries, dislocations, or fractures.\n* Neuropathies, including radiculopathies or myelopathies.\n* Severe medical conditions (e.g., tumors, fractures, neurological or systemic diseases).\n* Clinically relevant asymmetries.\n* Generalized musculoskeletal conditions such as fibromyalgia.",{"count":207,"type":23},30,[26],"Percutaneous electrical nerve stimulation (PENS) involves delivering electrical currents through fine filiform needles inserted near tissues such as muscles, ligaments, or nerves. It has been explored for various chronic pain conditions affecting the cervical and lumbar spine, as well as the upper and lower limbs. Despite its growing clinical use, the overall quality of evidence supporting PENS for chronic musculoskeletal pain remains limited. Most studies have applied the technique directly over nerve structures, and while some reviews have shown greater pain reduction compared to transcutaneous electrical nerve stimulation (TENS), the superiority of PENS has not been conclusively demonstrated. Research specifically examining its application on nerve tissues, particularly in the upper limbs, remains scarce. Some preliminary and single-case studies have reported improvements in pain and disability following PENS directed at the radial nerve, but these findings are limited by small sample sizes and the absence of control groups. The physiological mechanisms underlying PENS are still not fully understood, though both peripheral and central processes are believed to be involved. Evidence suggests that PENS can reduce local sensitivity to pressure pain through peripheral mechanisms and may also enhance descending inhibitory control by activating conditioned pain modulation at the central level. However, further studies are necessary to clarify these effects.\n\nSince to date, limited research has specifically examined the optimal PENS dosage, the present study aimed to compare two PENS dosage for improving muscle strength and pain pressure thresholds.",[123],[212,213,214],"Percutaneous electrical nerve stimulation","Strength","Pain pressure thresholds","2026-05-05",{"date":217,"type":40},"2026-05-08",{"date":219,"type":40},"2026-02-15",{"date":221,"type":23},"2026-07-30",{"name":46,"class":47},{"id":224,"slug":225,"hasResults":12,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":12,"sex":18,"minAge":231,"maxAge":172,"enrollmentInfo":232,"targetDuration":4,"studyType":24,"phases":233,"briefSummary":234,"conditions":235,"keywords":238,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":138},"100540323","effect-on-periodontal-phenotype-of-flapless-piezoincission-during-orthodontic-treatment-100540323","NCT06315348","Effect on Periodontal Phenotype of Flapless Piezoincission During Orthodontic Treatment","Effect on the Periodontal Phenotype of Flapless Alveolar Decortication and Augmentation During Orthodontic Treatment: A Randomized Clinical Trial","Piezo_Ortho","Inclusion Criteria:\n\nPatients will be consecutively selected among those attending the Faculty of Odontology, University Complutense (Madrid, Spain) looking for orthodontic therapy.\n\nThe inclusion criteria will be as follows:\n\n* patients requiring maxillary and\u002For mandible orthodontic treatment;\n* patients with permanent dentition in stage 5 or 6 of the cervical vertebral maturation method as described by Baccetti et al. (2002);\n* minimal to moderate maxillary and\u002For mandibular anterior crowding at baseline (arch length discrepancy from 3-8 mm); and\n* adequate oral health (i.e. periodontal health, absence of periapical infections and untreated caries).\n\nExclusion Criteria:\n\n* subjects with periodontitis stage III or IV (Papapanou et al., 2018);\n* subjects with poor oral hygiene (represented as full-mouth plaque scores (FMPS) \\>25%);\n* ongoing chronic drug therapy influencing bone metabolism (e.g. steroids, immunosuppressors or antiresorptive drugs);\n* subjects with uncontrolled systemic diseases (e.g. diabetes);\n* pregnancy and\n* subjects not willing to comply with the study visits","16 Years",{"count":119,"type":23},[26],"Research Question\n\nWhile the reduction in treatment times and the patient satisfaction after periodontally accelerated osteogenic orthodontics (PAOO) are well sustained in the scientific literature, there is still controversy regarding if grafting leads to i) change of the periodontal phenotype and ii) greater stability of post-orthodontic treatment outcomes, highlighting the need of controlled clinical trials.\n\nAims of the Project\n\nThe aim of this randomized clinical trial (RCT) is to compare piezocision-assisted orthodontics, concomitant to soft tissue grafting (volume-stable collagen matrix), with piezocision-assisted orthodontics, concomitant to bone grafting with a xenograft and a native collagen membrane, in orthodontic non-growing patients. The primary aim will be to determine the impact of this surgical protocol on the hard and soft tissue changes occurring on the buccal aspect of the dentition. Secondary objectives will include the assessment of the comparative impact on treatment duration, rate of tooth movements, presence of root resorption, periodontal parameters, bone level changes and patient-reported outcome measures (PROMs) between the two groups.",[236,237],"Dental Malocclusion","Maxillary Deficiency",[239,240,241,242],"Periodontal phenotype","Flapless piezoincision","Orthodontic tooth movement","Tissue augmentation","2026-05-04",{"date":217,"type":40},{"date":246,"type":40},"2024-04-20",{"date":248,"type":23},"2026-12",{"name":46,"class":47},{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":57,"sex":18,"minAge":58,"maxAge":257,"enrollmentInfo":258,"targetDuration":4,"studyType":24,"phases":259,"briefSummary":260,"conditions":261,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":263,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":138},"100521855","biofilm-accumulation-in-zirconia-vs-titanium-implants-100521855","NCT06075017","Biofilm Accumulation in Zirconia vs. Titanium Implants","Comparison of Biofilm Accumulation on the Surface of Zirconia Versus Titanium Implants. Randomized Controlled Pilot Clinical Trial","Inclusion Criteria:\n\n* Patients of both sexes of legal age.\n* Patients ASA I, II and III.\n* Subsequent to the placement of a single implant.\n* Patients who accept the surgery and sign the informed consent.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Patients who cannot attend follow-up appointments after surgery.\n* Patients with implants adjacent to the area to be treated.\n* Patients with uncontrolled periodontal pathology.\n* Systemic pathology that contraindicates the surgical procedure: hepatitis or other infectious diseases, oncological treatment, untreated or uncontrolled systemic pathology: diabetes mellitus, arterial hypertension, osteoporosis, heart failure, valvular heart disease, history of endocarditis, acute myocardial infarction less than 6 months ago, stroke less than 6 months ago, history of venous thromboembolism, arrhythmias, vitamin D deficiency, Parkinson's and Alzheimer's disease, dementia, psychiatric disorders, liver disease, COPD, chronic renal failure, immunosuppressed, autoimmune diseases, inflammatory bowel disease, digestive pathology, phosphocalcium metabolism diseases, hyper- or hypothyroidism, endocrinopathies, celiac disease, collagenosis, etc.\n* Pharmacological treatment with anticoagulants, antiaggregants, bisphosphonates, monoclonal antibodies, serotonin reuptake inhibitors, immunosuppressants, corticosteroids, antipsychotics.","99 Years",{"count":119,"type":23},[26],"The aim of this randomized clinical trial is to compare the amount and type of biofilm formed on the surface of zirconia implants compared to titanium implants.\n\nA pilot randomized clinical trial will be conducted in which 15 zirconia and 15 titanium single implants will be placed in different patients and the amount of total biofilm and different bacterial species will be evaluated at 3, 6 and 12 months after placement, in addition to bleeding on probing, plaque index, amount of keratinized gingiva, marginal bone loss and patient satisfaction. The Shapiro-Wilk normality test will be performed to determine whether each group follows a normal distribution. Once the distribution of the samples has been verified, we will proceed to apply a parametric test of repeated measures ANOVA or mixed ANOVA with Bonferroni correction, in order to observe what changes exist in the variables to be studied and if these will be statistically significant, establishing a significance level of P\\\u003C0.05. If the distribution does not comply with normality, the nonparametric Friedman test will be performed.",[262],"Implant Infection",{"date":217,"type":40},{"date":265,"type":23},"2027-12-01",{"date":267,"type":23},"2028-12-01",{"name":46,"class":47},{"id":270,"slug":271,"hasResults":12,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":275,"eligibilityCriteria":276,"healthyVolunteers":57,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":277,"targetDuration":4,"studyType":24,"phases":279,"briefSummary":280,"conditions":281,"keywords":286,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":138},"100633489","analysis-of-the-reliability-and-validity-of-laser-speckle-contrast-imaging-100633489","NCT07527351","Analysis of the Reliability and Validity of Laser Speckle Contrast Imaging","Analysis of the Reliability and Validity of Laser Speckle Contrast Analysis for the Measurement of Gingival Vascularisation","LSCI","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Non-smokers\n* Good systemic health\n* Good periodontal health\n* No current systemic medication\n* Good oral hygiene\n* For the retrospective surgical component: availability of previously documented clinical records from closed mucogingival surgical wounds or open palatal donor-site wounds, with prior consent allowing use of documented clinical material for research\n\nExclusion Criteria:\n\n* Pregnancy\n* Use of anti-inflammatory medication within 7 days before evaluation\n* Oral treatment within 6 months before evaluation\n* For the prospective healthy-gingiva component: any condition not compatible with good systemic or periodontal health\n* For the retrospective surgical component: absence of adequate previously documented clinical records or absence of prior consent for research use of the documented material",{"count":278,"type":23},24,[26],"This study is designed to validate laser speckle contrast imaging (LSCI) as a non-invasive method for measuring superficial gingival blood perfusion. Accurate assessment of vascularization is essential for understanding periodontal and peri-implant wound healing, yet current clinical methods are limited by subjective interpretation and low reproducibility. Repeated LSCI measurements will be performed in healthy gingival tissues and in tissues undergoing different mucogingival healing patterns, including primary and secondary intention healing. The study will also evaluate factors that may influence perfusion readings, such as angulation, retractors, mirror use, temperature, and heart rate. The primary objective is to determine the reproducibility of LSCI measurements and to support its use as a reliable tool for monitoring oral soft-tissue vascularization and healing.",[282,283,284,285],"Gingival Vascularization","Oral Soft Tissue Wound Healing","Laser Speckle Contrast Imaging","Periodontal Wound Healing",[287,275,288,289,290,291,292,293,294,295,296],"Laser speckle contrast imaging","Gingival microcirculation","Oral soft tissue wound healing","Periodontal wound healing","Mucogingival surgery","Palatal donor site","Blood perfusion","Reproducibility","Reliability","PeriCam PSI","2026-04-17",{"date":299,"type":40},"2026-04-22",{"date":301,"type":40},"2026-04-13",{"date":303,"type":23},"2026-05-20",{"name":46,"class":47},{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":12,"sex":18,"minAge":313,"maxAge":314,"enrollmentInfo":315,"targetDuration":4,"studyType":24,"phases":316,"briefSummary":317,"conditions":318,"keywords":321,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":138},"100630203","physical-activity-and-fitness-in-pediatric-inflammatory-bowel-disease-100630203","NCT07484620","Physical Activity and Fitness in Pediatric Inflammatory Bowel Disease","Effects of Physical Activity and Physical Fitness on Inflammation, Clinical Outcomes, and Quality of Life in Pediatric Inflammatory Bowel Disease","PAFIT-IBD","Inclusion Criteria:\n\n* Children and adolescents aged 6 to 17 years\n* Confirmed diagnosis of Crohn's disease or ulcerative colitis\n* Clinical remission or mild-to-moderate disease activity\n* Medical clearance to participate in physical activity\n* Ability to complete study assessments and follow-up procedures\n* Written informed consent from a parent or legal guardian and assent from the participant\n\nExclusion Criteria:\n\n* Severe disease activity or acute flare requiring hospitalization\n* Medical contraindications to exercise (e.g., severe cardiopulmonary disease, uncontrolled anemia, significant musculoskeletal conditions)\n* Major surgery within the previous 3 months\n* Participation in another interventional clinical trial\n* Cognitive or behavioral conditions preventing participation\n* Any condition considered unsafe by the investigators or treating physician","6 Years","17 Years",{"count":22,"type":23},[26],"Pediatric inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is a chronic condition associated not only with intestinal inflammation but also with reduced physical fitness, fatigue, impaired quality of life, and psychosocial difficulties. Although physical activity and physical fitness are recognized as important determinants of health in the general pediatric population, their role as modifiable prognostic factors in children and adolescents with IBD remains insufficiently studied, particularly using objective measures and longitudinal designs in hospital settings.\n\nThe present hospital-based study aims to investigate the effects of physical activity and physical fitness on inflammation, clinical outcomes, and quality of life in children and adolescents with IBD. The project comprises three phases: (1) an observational cross-sectional and longitudinal assessment, (2) a randomized controlled trial (RCT) evaluating a structured physical activity intervention, and (3) a medium-term follow-up at 6-12 months.\n\nPhysical activity will be assessed objectively using accelerometry and subjectively using validated questionnaires. Physical fitness will be evaluated with the ALPHA fitness battery adapted to the hospital setting, with cardiorespiratory fitness assessed by the 20-meter shuttle run test as the primary outcome of the RCT. Clinical outcomes will include objective inflammatory markers (fecal calprotectin and C-reactive protein), disease activity indices (PCDAI or PUCAI), musculoskeletal health, fatigue, cognitive functioning, and health-related quality of life. Nutritional status and dietary quality will also be assessed, and selected biological markers will be analyzed in a subsample.\n\nThe RCT will examine whether a 12-week supervised physical activity program improves cardiorespiratory fitness compared with usual care, and whether changes in fitness are accompanied by improvements in inflammatory burden and patient-reported outcomes. Longitudinal analyses will explore the sustainability of these effects over time.\n\nThis study will provide comprehensive, objective evidence on the role of physical activity and physical fitness as modifiable factors in pediatric IBD. The results are expected to inform clinical practice, support the integration of structured physical activity into multidisciplinary care, and contribute high-quality data for publication in international peer-reviewed journals.",[319,320],"Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis)","Inflamatory Bowel Disease",[322,323,324,325,326,327,328,329],"Pediatric Inflammatory Bowel Disease","Health-Related Quality of Life","Fecal Calprotectin","Physical Fitness","Cardiorespiratory Fitness","Accelerometry","Cognitive Function","Disease Activity","2026-03-19",{"date":332,"type":40},"2026-03-24",{"date":334,"type":23},"2026-04-01",{"date":336,"type":23},"2026-12-01",{"name":46,"class":47},{"id":339,"slug":340,"hasResults":12,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":12,"sex":18,"minAge":345,"maxAge":346,"enrollmentInfo":347,"targetDuration":4,"studyType":24,"phases":349,"briefSummary":350,"conditions":351,"keywords":353,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":4},"100630263","aerobic-interval-vs-continuous-training-on-heart-rate-power-decoupling-in-ischemic-heart-disease-100630263","NCT07485400","Aerobic Interval vs Continuous Training on Heart Rate-Power Decoupling in Ischemic Heart Disease","Effects of Long Extensive Aerobic Interval Training Versus Long Extensive Continuous Training on Heart Rate-Power Decoupling in Patients With Ischemic Heart Disease: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Confirmed diagnosis of cardiovascular disease requiring cardiac rehabilitation, with medical indication for a supervised exercise training program.\n* Prognostic risk classified as low or moderate according to the clinical risk stratification established in the unit, considering:\n\n  * Killip class I or II (absence or mild heart failure)¹.\n  * Absence of recent acute myocardial infarction (\\\u003C 1 month) or presence of a stable previous infarction.\n  * Stable and well-controlled cardiovascular symptoms.\n  * Physical capacity demonstrated in functional tests ≥ 5 METs, preferably \\> 7 METs for low-risk patients.\n* Age between 40 and 75 years.\n* Ability to perform physical exercise without absolute contraindications.\n* Written informed consent and willingness to attend the scheduled sessions twice per week for 8 weeks.\n\nExclusion Criteria:\n\n* High prognostic risk, defined by:\n\n  * Killip class \\> III (moderate to severe heart failure).\n  * Recent acute myocardial infarction (\\\u003C 1 month) with clinical instability.\n  * Active anginal symptoms or decompensated heart failure.\n  * Physical capacity \\\u003C 5 METs on functional testing, indicating severely reduced exercise capacity.\n* Presence of complex or unstable arrhythmias contraindicating vigorous physical exercise.\n* Concomitant diseases that may limit participation or compromise safety (e.g., advanced pulmonary disease, severe renal failure, severe neuromuscular disorders).\n* Absolute medical contraindications to maximal strength or interval training (e.g., aortic aneurysm, uncontrolled hypertension).\n* Participation in another clinical trial or concurrent rehabilitation program.\n* Inability to comply with attendance requirements or to follow the intervention protocol.","40 Years","75 Years",{"count":348,"type":23},48,[26],"This study is a randomized, parallel-group clinical trial with assessor and statistical analyst blinding, conducted at a single center. Participants with stable ischemic heart disease enrolled in a cardiac rehabilitation program will be randomly allocated to one of two aerobic exercise interventions: long extensive continuous aerobic training (zone 2) or long extensive aerobic interval training (zone 3). Both groups will participate in supervised exercise sessions twice weekly for a period of 8 weeks, integrated into the standard cardiac rehabilitation program.\n\nAssessments will be performed at baseline, immediately after the intervention period (8 weeks), and after a 4-week follow-up period without supervised training to evaluate potential detraining effects. The primary outcome is heart rate-power decoupling during a prolonged submaximal cycling exercise test, used as an indicator of cardiovascular efficiency. Secondary outcomes include heart rate response during submaximal exercise, exercise tolerance, heart rate recovery, blood pressure, functional capacity, quality of life, and adherence to the training program.\n\nThe objective of this study is to compare the effects of long extensive aerobic interval training versus long extensive continuous training on heart rate-power decoupling and related cardiovascular and functional outcomes in patients with ischemic heart disease undergoing cardiac rehabilitation.",[352],"Stable Coronary Artery Disease (CAD), Myocardial Infarction",[354,355,356,357,358],"Cardiac rehabilitation","High-Intensity Interval Training","Coronary Artery Disease","Exercise Therapy","Myocardial Infarction","2026-03-16",{"date":361,"type":40},"2026-03-20",{"date":363,"type":23},"2026-03-17",{"date":365,"type":23},"2026-07-03",{"name":46,"class":47},{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":373,"eligibilityCriteria":374,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":375,"enrollmentInfo":376,"targetDuration":4,"studyType":24,"phases":377,"briefSummary":378,"conditions":379,"keywords":381,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":138},"100628804","effects-of-hmb-and-rehabilitation-program-in-athletes-with-patellar-tendinopathy-100628804","NCT07466407","Effects of HMB and Rehabilitation Program in Athletes With Patellar Tendinopathy","Effects of Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation in Athletes With Patellar Tendinopathy","HMB_TEN","Inclusion Criteria:\n\n* Age between 18 and 49 years\n* Clinical diagnosis of patellar tendinopathy confirmed by a physician and physiotherapist\n* Competitive athlete in sports involving repetitive knee loading (e.g., basketball, volleyball, handball, athletics)\n* Minimum training frequency of three sessions per week\n* No knee surgery within the previous 12 months\n* No nutritional supplementation within the previous 3 months\n* No injection therapy (analgesics or platelet-rich plasma) within the previous 12 months\n* Non-smoker\n* Signed informed consent\n\nExclusion Criteria:\n\n* Any musculoskeletal injury other than patellar tendinopathy affecting performance\n* Systemic disease affecting musculoskeletal function\n* Inability to comply with the rehabilitation or supplementation protocol","49 Years",{"count":207,"type":23},[26],"This randomized, double-blind, placebo-controlled clinical trial evaluates the effects of oral beta-hydroxy-beta-methylbutyrate (HMB) supplementation combined with an eccentric exercise and extracorporeal shockwave rehabilitation program on pain, tendon morphology, and neuromuscular performance in athletes with patellar tendinopathy.\n\nThirty athletes with a confirmed diagnosis of patellar tendinopathy are randomized to receive either HMB supplementation (3 g\u002Fday) or placebo during an 8-week rehabilitation program. Participants are evaluated at baseline, week 4, and week 8.\n\nThe primary outcome is pain and functional limitation assessed using the Victorian Institute of Sport Assessment-Patella (VISA-P) questionnaire. Secondary outcomes include patellar tendon thickness measured by ultrasound imaging, countermovement jump (CMJ) performance, and neuromuscular performance variables derived from an incremental squat test using a linear position transducer.\n\nThe aim of the study is to determine whether HMB supplementation enhances clinical recovery and neuromuscular performance when combined with a standardized rehabilitation program compared with placebo.",[380],"Patellar Tendinopathy",[382,383,384,385,386,387,388],"Tendinopathy","HMB","Rehabilitation","Knee pain","Sports injury","Nutritional supplement","Beta-hydroxy-beta-methylbutyrate","2026-03-09",{"date":391,"type":40},"2026-03-12",{"date":393,"type":23},"2026-03-01",{"date":395,"type":23},"2026-07-01",{"name":46,"class":47},{"id":398,"slug":399,"hasResults":12,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":404,"targetDuration":4,"studyType":24,"phases":405,"briefSummary":406,"conditions":407,"keywords":409,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":424,"leadSponsor":426,"locationsCount":138},"100626056","theravex-oral-and-theravex-tissue-care-plus-in-the-healing-process-of-mucogingival-surgery-100626056","NCT07430670","Theravex Oral and Theravex Tissue Care Plus in the Healing Process of Mucogingival Surgery","Clinical Study on the Efficacy of Theravex Oral and Theravex Tissue Care Plus in Periodontal Surgery\" Modified Free Gingival Graft for the Treatment of RT1-RT2: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Healthy patients aged ≥ 18 years.\n* Patients with at least one mandibular incisor presenting a gingival recession RT1-RT2 and requiring a free gingival graft.\n* Periodontal health in either an intact or reduced periodontium (Chapple et al., 2018) with a plaque index ≤ 20% (O'Leary et al., 1972).\n* Initial probing depth ≤ 3 mm in the treated teeth.\n* No dental mobility (grade ≤ 1) in the treated teeth.\n* Well-defined CEJ\n* Agreement to take part in this study (signed informed consent).\n\nExclusion Criteria:\n\n* Smokers ≥10 cigarettes\u002Fday.\n* Patients treated with Theravex \\[IS1.1\\]\\[ma1.2\\]previously.\n* Untreated parafunctional habits.\n* Restorations that cannot be removed for proper treatment.\n* Pregnant patients or cases with uncertain pregnancy status (self-reported).\n* Patients with uncontrolled systemic diseases, neurological, psychiatric disorders, or other known conditions capable of influencing the results of the study.\n* Patients not attending follow-ups or not signing informed consent.",{"count":207,"type":23},[26],"This clinical study assesses the efficacy of two novel bioactive solutions, Theravex Oral and Theravex Tissue Care Plus, in enhancing soft tissue healing after periodontal surgery. The study focuses on patients undergoing a Modified Free Gingival Graft (M-FGG) technique to treat gingival recessions around mandibular incisors. Participants are randomly assigned to a test group receiving the Theravex treatment or a control group receiving a saline placebo. The primary goal is to measure the impact of these solutions on root coverage and other key outcomes, such as tissue gain, color integration, and postoperative pain, over a one-year period.",[408],"Gingival Recession, Localized",[410,411,412,413,414,415,416,417,418,419],"Gingiva Recession","Modified Free Gingival Graft (M-FGG)","Theravex (Oral and Tissue Care Plus)","Bone Bioactive Liquid","Root Coverage","Soft Tissue Healing","Neovascularization","Spectrophotometry","Ultrasonography","Randomized Clinical Trial (RCT)","2026-02-17",{"date":422,"type":40},"2026-02-24",{"date":420,"type":40},{"date":425,"type":23},"2027-07-06",{"name":46,"class":47},{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":4,"eligibilityCriteria":433,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":434,"targetDuration":4,"studyType":24,"phases":436,"briefSummary":437,"conditions":438,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":138},"100608338","changes-in-soft-tissue-thickness-following-multiple-coronally-advanced-tunnel-mcat-vs-vestibular-incision-subperiosteal-tunnel-access-vista-100608338","NCT07200258","Changes in Soft Tissue Thickness Following Multiple Coronally Advanced Tunnel (MCAT) vs Vestibular Incision Subperiosteal Tunnel Access (VISTA)","Changes in Soft Tissue Thickness Following Multiple Coronally Advanced Tunnel (MCAT) vs Vestibular Incision Subperiosteal Tunnel Access (VISTA): A Randomized Clinical Trial With 3D Volumetric Analysis","Inclusion Criteria:\n\n* Periodontally and systemically healthy adults (age ≥ 18 years).\n* At least two adjacent sites exhibiting gingival recessions classified as recession type 1 (RT1) o type 2 (RT2) (Cairo et al., 2011), associated with dental hypersensitivity or aesthetic concerns.\n* Presence ≥2 mm depth on at least one recession\n* Smokers ≤ 10 cigarettes.\n* Full-mouth plaque and bleeding scores ≤20%.\n* Patients being able to maintain good oral hygiene.\n\nExclusion Criteria:\n\n* Compromised general health.\n* Pregnancy or attempting to get pregnant (self-reported).\n* Untreated periodontal diseases\n* Presence of: (i) severe tooth malposition; (ii) root caries or inadequate prosthetic restorations; (iii) previous periodontal plastic surgery at the experimental sites.\n* Smokers \\>10 cigarettes",{"count":435,"type":23},44,[26],"This randomized clinical trial will compare two surgical methods for treating multiple adjacent gingival recessions (types RT1 and RT2): the Modified Coronally Advanced Tunnel (MCAT) and the Vestibular Incision Subperiosteal Tunnel Access (VISTA). Both methods will use connective tissue grafts (CTG), which are the best way to cover roots.\n\nThe main objective is to use three-dimensional (3D) digital volumetric analysis to look at how the thickness of soft tissue has changed after six and 12 months. Secondary outcomes include root coverage, esthetic outcomes, gingival health parameters, hypersensitivity, patient satisfaction, and wound healing quality.\n\nThere will be 44 volunteers, and they will be randomly assigned to one of the two surgical methods. Under the same settings, periodontal specialists in training will undertake the procedures at the Universidad Complutense de Madrid. There will be follow-up evaluations at different times up to 12 months after the procedure. The results of this study will help determine whether remote incisions via the VISTA technique offer improved outcomes compared to the MCAT technique.",[439],"Gingival Recession","2026-02-11",{"date":442,"type":40},"2026-02-13",{"date":444,"type":40},"2025-10-15",{"date":446,"type":23},"2028-07",{"name":46,"class":47},{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":4,"eligibilityCriteria":454,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":58,"enrollmentInfo":455,"targetDuration":4,"studyType":24,"phases":457,"briefSummary":458,"conditions":459,"keywords":461,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":4},"100622410","comparison-of-maxillary-protraction-using-tooth-borne-facemask-versus-skeletal-anchorage-chin-plate-in-class-iii-growing-patients-100622410","NCT07383259","Comparison of Maxillary Protraction Using Tooth-borne Facemask Versus Skeletal Anchorage Chin-plate in Class III Growing Patients","Skeletal and Dentoalveolar Effects of Tooth-borne Facemask Versus Skeletal Anchorage Chin-plate Maxillary Protraction in Growing Class III Patients.","Inclusion Criteria\n\n* Growing patients (CVS1-CVS3)\n* Patent midpalatal suture (stages A-C)\n* Skeletal Class III malocclusion (ANB \\\u003C 0°, Wits \\\u003C -2 mm)\n* Presence of anterior crossbite or edge-to-edge incisal relationship Exclusion Criteria\n* Severe craniofacial asymmetry\n* Evidence of active condylar growth\n* Previous orthodontic treatment\n* Craniofacial malformations or syndromes\n* Systemic diseases or medications affecting growth or bone metabolism",{"count":456,"type":23},36,[26],"This retrospective non-randomized controlled clinical trial aimed to compare the skeletal and dentoalveolar effects of two orthopedic treatment protocols for skeletal Class III malocclusion in growing patients: a conventional tooth-borne rapid maxillary expansion combined with facemask therapy, and a hybrid skeletal anchorage expander combined with chin-plate traction. Lateral cephalometric changes before and after maxillary protraction were analyzed to assess sagittal skeletal correction and dentoalveolar effects.",[460],"Skeletal Class III Malocclusion",[462,463,464,465,466,467,468],"Class III malocclusion","skeletal anchorage","face-mask","Palatal expander","tooth-borne rapid maxillary expander","hybrid skeletal anchorage expander","chin-plate","2026-01-28",{"date":471,"type":40},"2026-02-03",{"date":473,"type":23},"2026-02",{"date":475,"type":23},"2027-03",{"name":46,"class":47},{"id":478,"slug":479,"hasResults":12,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":4,"eligibilityCriteria":483,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":484,"targetDuration":4,"studyType":24,"phases":486,"briefSummary":487,"conditions":488,"keywords":495,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":510,"locationsCount":4},"100621908","effects-of-controlled-breathing-on-cardiorespiratory-variables-in-multiple-myeloma-100621908","NCT07376733","Effects of Controlled Breathing on Cardiorespiratory Variables in Multiple Myeloma","Efficacy of a Controlled Breathing and Therapeutic Exercise Program on Cardiorespiratory Variables in Patients With Multiple Myeloma","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Confirmed diagnosis of multiple myeloma, currently undergoing active treatment with daratumumab, and under clinical follow-up by the Hematology Department of HU12O.\n* Explicit medical indication for supervised physical activity issued by the responsible hematologist and documented in the medical record.\n* No scheduled hematopoietic stem cell transplantation within the 60 days following the planned start date of the intervention (verified through medical record review).\n* Functional status of ECOG 0-2 (Eastern Cooperative Oncology Group), assessed by a healthcare professional from the Hematology Department, ensuring the ability to perform at least basic and light instrumental activities of daily living, including independent ambulation.\n* Access to a smartphone with stable internet connection, required for monitoring and recording adherence to the intervention.\n* Ability to provide written informed consent, demonstrating understanding of the study's nature, purpose, and procedures.\n\nExclusion Criteria:\n\n* Medical risk contraindicating exercise or breathing techniques:\n\n  * Clinically significant cardiovascular disease, including:decompensated heart failure, acute myocardial infarction within the past 3 months, clinically uncontrolled arrhythmias, unstable angina, acute-phase deep vein thrombosis or pulmonary embolism, pacemakers or cardiac devices whose monitoring parameters contraindicate supervised exercise according to cardiology.\n  * Severe decompensated respiratory disease, such as acute exacerbation of COPD, severe respiratory insufficiency, or persistently low resting oxygen saturation \\\u003C 90% (not correctable).\n* High musculoskeletal or bone risk:\n\n  * Extensive lytic bone lesions, high risk of pathological fracture, or unstable vertebral fracture, documented by imaging or based on the assessment of the Hematology\u002FTraumatology specialist.\n  * Uncontrolled pain that prevents safe participation in an exercise program.\n* Hematologic or systemic conditions contraindicating exercise:\n\n  * Severe anemia: hemoglobin \\\u003C 9 g\u002FdL in women or \\\u003C 8 g\u002FdL in men (latest laboratory test ≤ 14 days).\n  * Active systemic infection contraindicating exercise, fever ≥ 38 °C, or neutropenia \\\u003C 0.5 × 10⁹\u002FL.\n  * Severe cytopenias that, in the opinion of the hematologist, preclude moderate exercise.\n* Functional or procedural limitations:\n\n  * Inability to remain in the supine position for ≥ 5 minutes, required for part of the breathing intervention.\n  * Confirmed pregnancy or reasonable suspicion of pregnancy.\n  * Severe cognitive impairment, major psychiatric disorders, or neurological diseases that limit understanding of the procedures or safe participation.\n  * Significant difficulty understanding the language (spoken or written) that prevents following essential instructions or completing validated questionnaires.",{"count":485,"type":23},26,[26],"A randomized, parallel, double-blind, controlled, clinical trial. Two groups of participants will be included, both receiving a therapeutic exercise intervention and an educational session on the importance of proper breathing over a 6-week period. One of the groups will additionally perform a home-based controlled breathing exercise protocol. Pre- and post-intervention assessments (6 weeks) will be conducted, along with a follow-up evaluation 4 weeks after completion of the intervention. The goal is to determine the effectiveness of adding a controlled breathing exercise program to a therapeutic exercise intervention on cardiorespiratory variables in individuals with multiple myeloma.",[489,490,491,492,493,494],"Multiple Myeloma (MM)","Breathing Techniques","Breathing Exercises","Exercise Activity","Diaphragmatic Breathing","Heart Rate Variability (HRV)",[496,497,498,499,500,501,502],"multiple myeloma","Breathing","Diaphragmatic breathing","Slow breathing","exercise activity","Breathing exercises","heart rate variability","2026-01-21",{"date":505,"type":40},"2026-01-29",{"date":507,"type":23},"2026-01",{"date":509,"type":23},"2026-09",{"name":46,"class":47},{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":517,"eligibilityCriteria":518,"healthyVolunteers":57,"sex":18,"minAge":4,"maxAge":58,"enrollmentInfo":519,"targetDuration":4,"studyType":24,"phases":521,"briefSummary":522,"conditions":523,"keywords":525,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":530,"completionDateStruct":532,"leadSponsor":534,"locationsCount":4},"100621756","immediately-loaded-implants-with-or-without-horizontal-augmentation-100621756","NCT07374757","Immediately Loaded Implants With or Without Horizontal Augmentation","Clinical Outcomes of Immediately Loaded Implants With Buccal Dehiscence Treated by Horizontal Augmentation Compared With Immediately Loaded Implants Without Regeneration Techniques","ILHA","Inclusion Criteria:\n\nAdult patients requiring dental implant placement Presence of buccal dehiscence at the implant site Indication for immediate loading Ability to provide written informed consent\n\nExclusion Criteria:\n\nUncontrolled systemic diseases Active periodontal disease Heavy smoking exceeding predefined limits Conditions contraindicating oral surgery",{"count":520,"type":23},20,[26],"This study aims to compare the clinical success and patient-reported outcomes of immediately loaded dental implants placed in sites with buccal dehiscence treated by horizontal augmentation versus immediately loaded implants placed without regeneration techniques.",[524],"Bone Augmentation Associated With Immediate Loading",[526,527],"Inmediate loading","horizontal bone regeneration","2026-01-20",{"date":505,"type":40},{"date":531,"type":23},"2026-01-08",{"date":533,"type":23},"2027-12-11",{"name":46,"class":47},{"id":536,"slug":537,"hasResults":12,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":4,"eligibilityCriteria":541,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":542,"targetDuration":4,"studyType":24,"phases":544,"briefSummary":545,"conditions":546,"keywords":548,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":558,"leadSponsor":560,"locationsCount":138},"100620929","accuracy-of-metal-sleeve-free-fully-guided-implant-surgery-100620929","NCT07364006","Accuracy of Metal Sleeve-Free Fully Guided Implant Surgery","Evaluation of Accuracy in Fully Guided Dental Implant Surgery Using 3D-Printed Surgical Guides Without Metal Sleeves: A Split-Mouth In Vivo Study","Inclusion Criteria:\n\n* Partially or fully edentulous patients requiring fixed complete-arch rehabilitation with dental implants.\n* Patients classified as ASA I or ASA II.\n* Adult patients aged 18 years or older.\n* Ability to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Patients classified as ASA III or ASA IV.\n* Patients with medical conditions that contraindicate dental implant surgery.\n* Inability or unwillingness to provide informed consent.",{"count":543,"type":23},15,[26],"This clinical trial aims to evaluate the in vivo accuracy of fully guided dental implant surgery using 3D-printed surgical guides without metal sleeves. The study is designed as a split-mouth clinical trial and will be conducted in partially or fully edentulous adult patients requiring complete-arch rehabilitation with dental implants.\n\nThe primary objective of the study is to assess the accuracy of implant placement by comparing the virtually planned implant positions with the actual clinical positions achieved after guided surgery. Accuracy will be evaluated by analyzing linear and angular deviations between planned and placed implants.\n\nParticipants will undergo a fully guided implant placement procedure using metal sleeve-free surgical guides. Two different drilling channel diameters (standard and reduced) will be randomly assigned in a split-mouth manner. Postoperative intraoral scans and cone-beam computed tomography (CBCT) scans with scan bodies will be obtained to register the final implant positions.\n\nThe planned and achieved implant positions will be compared using three-dimensional analysis software to quantify deviations and determine whether the use of metal sleeve-free guides and reduced drilling diameters influences implant placement accuracy.",[547],"Edentulism",[549,550,551,552,553],"Guided implant surgery","Dental implants","Surgical guide accuracy","Metal sleeve-free surgical guides","3D-printed surgical guides","2026-01-16",{"date":556,"type":40},"2026-01-23",{"date":106,"type":40},{"date":559,"type":23},"2026-08-01",{"name":46,"class":47},{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":4,"eligibilityCriteria":567,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":568,"targetDuration":4,"studyType":24,"phases":570,"briefSummary":571,"conditions":572,"keywords":574,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":578,"completionDateStruct":579,"leadSponsor":580,"locationsCount":4},"100617001","effects-of-controlled-breathing-added-to-therapeutic-exercise-in-multiple-myeloma-100617001","NCT07312942","Effects of Controlled Breathing Added to Therapeutic Exercise in Multiple Myeloma","Effects of Adding a Controlled Breathing Protocol to a Therapeutic Exercise Program in Adults With Multiple Myeloma","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Confirmed diagnosis of multiple myeloma, currently undergoing active treatment with daratumumab, and under clinical follow-up by the Hematology Department of HU12O.\n* Explicit medical indication for supervised physical activity issued by the responsible hematologist and documented in the medical record.\n* No scheduled hematopoietic stem cell transplantation within the 60 days following the planned start date of the intervention (verified through medical record review).\n* Functional status of ECOG 0-2 (Eastern Cooperative Oncology Group), assessed by a healthcare professional from the Hematology Department, ensuring the ability to perform at least basic and light instrumental activities of daily living, including independent ambulation.\n* Access to a smartphone with stable internet connection, required for monitoring and recording adherence to the intervention.\n* Ability to provide written informed consent, demonstrating understanding of the study's nature, purpose, and procedures.\n\nExclusion Criteria:\n\n* Medical risk contraindicating exercise or breathing techniques:\n\n  +Clinically significant cardiovascular disease, including: decompensated heart failure, acute myocardial infarction within the past 3 months, clinically uncontrolled arrhythmias, unstable angina, acute-phase deep vein thrombosis or pulmonary embolism, pacemakers or cardiac devices whose monitoring parameters contraindicate supervised exercise according to cardiology.\n  * Severe decompensated respiratory disease, such as acute exacerbation of COPD, severe respiratory insufficiency, or persistently low resting oxygen saturation \\\u003C 90% (not correctable).\n* High musculoskeletal or bone risk:\n\n  * Extensive lytic bone lesions, high risk of pathological fracture, or unstable vertebral fracture, documented by imaging or based on the assessment of the Hematology\u002FTraumatology specialist.\n  * Uncontrolled pain that prevents safe participation in an exercise program.\n* Hematologic or systemic conditions contraindicating exercise:\n\n  * Severe anemia: hemoglobin \\\u003C 9 g\u002FdL in women or \\\u003C 8 g\u002FdL in men (latest laboratory test ≤ 14 days).\n  * Active systemic infection contraindicating exercise, fever ≥ 38 °C, or neutropenia \\\u003C 0.5 × 10⁹\u002FL.\n  * Severe cytopenias that, in the opinion of the hematologist, preclude moderate exercise.\n* Functional or procedural limitations:\n\n  * Inability to remain in the supine position for ≥ 5 minutes, required for part of the breathing intervention.\n  * Confirmed pregnancy or reasonable suspicion of pregnancy.\n  * Severe cognitive impairment, major psychiatric disorders, or neurological diseases that limit understanding of the procedures or safe participation.\n  * Significant difficulty understanding the language (spoken or written) that prevents following essential instructions or completing validated questionnaires.",{"count":569,"type":23},32,[26],"A randomized, parallel, double-blind, controlled, multicenter clinical trial with two intervention arms. Two groups of participants will be included, both receiving a therapeutic exercise intervention and an educational session on the importance of proper breathing over a 6-week period. One of the groups will additionally perform a home-based controlled breathing exercise protocol. Pre- and post-intervention assessments (6 weeks) will be conducted, along with a follow-up evaluation 4 weeks after completion of the intervention.\n\nThe goal is to determine the effectiveness of adding a controlled breathing exercise program to a therapeutic exercise intervention on somatic symptoms in individuals with multiple myeloma",[573,490,491,492,493],"Multiple Myeloma",[575,497,498,499,500,501],"Multiple myeloma","2026-01-15",{"date":528,"type":40},{"date":507,"type":23},{"date":79,"type":23},{"name":46,"class":47},{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":586,"acronym":587,"eligibilityCriteria":588,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":147,"enrollmentInfo":589,"targetDuration":4,"studyType":24,"phases":590,"briefSummary":591,"conditions":592,"keywords":594,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":618,"lastUpdatePostDateStruct":619,"startDateStruct":620,"completionDateStruct":621,"leadSponsor":623,"locationsCount":138},"100620763","long-hold-yielding-isometric-exercise-for-patellar-tendinopathy-in-weightlifting-athletes-100620763","NCT07361848","Long-Hold Yielding Isometric Exercise for Patellar Tendinopathy in Weightlifting Athletes","Randomized Controlled Trial Evaluating the Effects of Long-Hold Yielding Isometric Exercise on Pain, Function, Vascularity, and Mechanical Properties of the Patellar Tendon in Competitive Weightlifting Athletes","QuantFlow","Inclusion Criteria:\n\n1. Competitive weightlifting athletes (Olympic weightlifting or CrossFit) training ≥3 times per week.\n2. Age 18-45 years.\n3. Symptom duration of at least 6 weeks.\n4. Presence of vascularized patellar tendinopathy, defined as Doppler-detectable intratendinous neovascularization using standardized settings.\n5. VISA-P score \\\u003C 80 at baseline.\n6. Ability to perform loaded lower-limb exercises safely.\n7. Willingness to refrain from other structured isometric interventions focused on the patellar tendon during the study period.\n8. Ability to provide informed consent.\n9. Sex\u002FGender requirement: both men and women eligible; the study includes sex-stratified analysis to examine potential sex-based differences in tendon response.\n\nExclusion Criteria:\n\n1. Previous knee surgery within the past 12 months.\n2. Partial or complete patellar tendon rupture (confirmed clinically or by ultrasound).\n3. Coexisting knee conditions (e.g., meniscal tear, ACL\u002FPCL injury, patellofemoral joint instability) that significantly affect load tolerance.\n4. Systemic diseases affecting tendon health (e.g., diabetes, rheumatoid arthritis, connective tissue disorders).\n5. Corticosteroid injection in the patellar tendon within the last 6 months.\n6. Participation in other clinical trials involving exercise or tendon-loading interventions.\n7. Neuromuscular or medical conditions limiting safe performance of isometric or plyometric exercise.\n8. Pregnancy.\n9. Inability to commit to follow-up assessments at 8, 12, and 24 weeks.",{"count":278,"type":23},[26],"The goal of this clinical trial is to evaluate whether a long-hold yielding isometric exercise program improves pain, tendon vascularity, mechanical properties, and functional performance in weightlifting athletes with patellar tendinopathy. The study will also explore the safety and feasibility of this exercise strategy.\n\nResearchers will compare the long-hold isometric intervention with routine training recommendations to determine its effects on symptoms and tendon function.\n\nParticipants will perform the supervised isometric protocol and complete pain ratings, functional tests, and ultrasound evaluations of the patellar tendon.",[593],"Patellar Tendinopathy \u002F Jumpers Knee",[595,596,597,598,599,600,601,602,603,604,605,606,607,608,609,610,611,612,613,614,615,616,617],"patellar tendinopathy","long hold yielding isometrics","weightlifting athletes","tendon vascularity","shear-wave elastography","quantitative ultrasound","echotexture","echostructure","ehointensity","echovariation","doppler imaging","tendon stifness","stress-strain curve","young's modulus","biomechanics","jumper's knee","iPulley isokinetic","countermovement jump","force platform biomechanics","tissue mechanical properties","musculoskeletal imaging","clincal trial","randomized controlled trial","2026-01-14",{"date":556,"type":40},{"date":136,"type":23},{"date":622,"type":23},"2028-04-01",{"name":46,"class":47},{"id":625,"slug":626,"hasResults":12,"nctId":627,"briefTitle":628,"officialTitle":629,"acronym":4,"eligibilityCriteria":630,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":631,"targetDuration":4,"studyType":24,"phases":632,"briefSummary":634,"conditions":635,"keywords":637,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":618,"lastUpdatePostDateStruct":645,"startDateStruct":646,"completionDateStruct":647,"leadSponsor":649,"locationsCount":138},"100614503","phase-4-effectiveness-of-a-sodium-hyaluronate-001-and-sh-oligopeptide-85-sp-mouthwash-for-the-treatment-of-symptomatic-oral-lichen-planus-100614503","NCT07280442","Effectiveness of a Sodium Hyaluronate 0.01% and Sh-Oligopeptide-85 SP Mouthwash for the Treatment of Symptomatic Oral Lichen Planus","Effectiveness of a Sodium Hyaluronate 0.01% and Sh-Oligopeptide-85 SP Mouthwash for the Treatment of Symptomatic Oral Lichen Planus. A Randomized Clinical Trial","Patients must meet the following inclusion criteria:\n\n1. Patients aged ≥18 years.\n2. Patients with a clinical and histological diagnosis of OLP according to the criteria of the American Academy of Oral and Maxillofacial Pathology (Cheng et al., 2016).\n3. Symptomatic patients, i.e., those presenting atrophic-erosive or ulcerative OLP lesions.\n4. Patients with a VAS score ≤ 6.\n\nExclusion criteria will be:\n\n1. Pregnant or breastfeeding women.\n2. Allergy to the components of the Tectum-11® mouthwash.\n3. Patients receiving corticosteroids, immunosuppressants, hydroxychloroquine, or retinoids at the time of recruitment.\n4. Patients with lichenoid lesions: drug-induced lichenoid reactions, contact lichenoid lesions, or graft-versus-host disease.\n5. Use of topical corticosteroids within the previous 4 weeks or systemic treatment within the previous 8 weeks.\n6. Use of other mouthrinses for plaque control.\n7. Patients unwilling to sign the informed consent form.\n8. Patients with a VAS score \\> 6.\n\nThe presence of any of the following criteria will lead to withdrawal of the participant from the study:\n\n1. Failure to attend follow-up visits.\n2. Occurrence of adverse events deemed clinically relevant by the investigator.\n3. The patient reports that they no longer wish to participate in the study.\n4. Development of oral or systemic lesions that meet any of the exclusion criteria.\n5. Non-adherence to the treatment regimen, defined as failure to follow the protocol for more than two consecutive weeks.",{"count":119,"type":23},[633],"PHASE4","Annex 1. Patient Information and Informed Consent for the Study Study Title: Effectiveness of a sodium hyaluronate 0.01% and Sh-Oligopeptide-85 SP mouthwash for the treatment of symptomatic oral lichen planus: a randomized clinical trial.\n\nPrincipal Investigator: Dr. Rosa Mª López-Pintor Muñoz, Associate Professor, Department of Clinical Dental Specialties, Faculty of Dentistry, Complutense University of Madrid.\n\nDear Sir\u002FMadam, Participants are invited to take part in a study evaluating the effectiveness of a mouthwash designed to reduce oral lichen planus-related lesions and pain.\n\nStudy Objective The primary aim of this study is to evaluate and compare the effect of Tectum mouthwash (containing sodium hyaluronate and Sh-Oligopeptide-85) versus a corticosteroid mouthwash (provided at no cost to participants) in reducing pain and lesion size.\n\nEligible participants with oral lichen planus and associated discomfort will receive either Tectum mouthwash or a corticosteroid mouthwash to use after toothbrushing for the first two weeks three times daily, twice daily in the third week, and once daily in the fourth week of treatment.\n\nParticipants will be randomly assigned to receive either Tectum mouthwash or the corticosteroid mouthwash through a process comparable to a coin toss. Treatment allocation will be blinded. Neither participants nor the attending clinician will know which treatment is being administered. Participants must use the assigned mouthwash for 4 weeks according to the clinician's instructions and attend visits at the Faculty of Dentistry at 1, 2, 3, and 4 weeks to assess improvement.\n\nAt the first visit, a series of data will be recorded, and oral lichen planus lesions and pain will be assessed. The same variables will be evaluated at 1, 2, 3, and 4 weeks to determine treatment effectiveness. Participants will also complete two questionnaires assessing pain intensity and the impact of symptoms on quality of life. During the 4-week treatment period, the use of any other mouthwashes will not be permitted, and antibiotics or anti-inflammatory medications may not be used.\n\nThe investigational mouthwash is already marketed and has been used to treat conditions such as oral mucositis and xerostomia with favorable results; therefore, potential benefit in oral lichen planus is anticipated.\n\nIf pain occurs, 400 mg ibuprofen may be taken every 8 hours as needed. If ibuprofen is taken, each dose should be recorded and reported to the attending healthcare professional.\n\nVoluntary Participation Participation is entirely voluntary, and non-participation is permitted. Participants may withdraw at any time without providing an explanation and without any disadvantage to clinical care. Refusal to participate or withdrawal will not affect the relationship between participants and the institution.\n\nStudy Procedures The dentist providing care in the Diploma of Specialization in Oral Medicine will invite eligible individuals to participate and will provide detailed instructions. The attending dentist will request completion of a questionnaire containing study-required information. If participation is accepted, lesions will be assessed, and questionnaires will be completed.\n\nThe attending dentist will instruct participants on product use: three times daily during weeks 1 and 2, twice daily during week 3, and once daily during week 4. Follow-up appointments at 1, 2, 3, and 4 weeks will be scheduled to evaluate the same variables and to repeat the questionnaires.\n\nRisks This study does not present additional risks beyond routine care. Improvement may not occur with use of the mouthwash. Response to corticosteroids and to the investigational treatment may vary.\n\nConfidentiality Confidentiality will be maintained. All information collected during this research will be treated as privileged and documented in coded format. Participants have the right to access and rectify personal data at any time, as established by Organic Law 3\u002F2018 of December 5 on the Protection of Personal Data and Guarantee of Digital Rights. In accordance with data protection regulations, consent may be revoked and rights of access, modification, opposition, and deletion of data may be exercised. Rights to limit the processing of inaccurate data, request a copy of the data, or request transfer of data to a third party (portability), as applicable, may also be exercised.\n\nTo exercise these rights, contact may be made with the principal investigator (Dr. Rosa Mª López-Pintor Muñoz, Department of Clinical Dental Specialties, Faculty of Dentistry, Complutense University of Madrid). Participants may also contact the Spanish Data Protection Agency if concerns are not resolved satisfactorily.\n\nParticipant identity and any information that could identify a participant will not be disclosed.",[636],"Oral Lichen Planus",[638,639,640,641,642,643,644],"oral lichen planus","RCT","OPMD","treatment","topical treatment","Sh-Oligopeptide-85 SP Mouthwash","Sodium hyaluronate 0.01%",{"date":554,"type":40},{"date":531,"type":23},{"date":648,"type":23},"2027-06-15",{"name":46,"class":47},{"id":651,"slug":652,"hasResults":12,"nctId":653,"briefTitle":654,"officialTitle":654,"acronym":655,"eligibilityCriteria":656,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":657,"enrollmentInfo":658,"targetDuration":4,"studyType":24,"phases":660,"briefSummary":661,"conditions":662,"keywords":665,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":675,"lastUpdatePostDateStruct":676,"startDateStruct":678,"completionDateStruct":679,"leadSponsor":681,"locationsCount":138},"100613931","phase-4-percutaneous-electrical-nerve-stimulation-as-alternative-to-nerve-blocks-in-anesthesia-pain-medicine-and-rehabilitation-of-nonspecific-chronic-pain-100613931","NCT07273006","Percutaneous Electrical Nerve Stimulation As Alternative To Nerve Blocks In Anesthesia, Pain Medicine And Rehabilitation Of Nonspecific Chronic Pain","PENSAR","Inclusion Criteria:\n\n* Participants with chronic LBP lasting at least three months and clinical suspicion of facet joint pain.\n* A balanced sex distribution and a wide range of body mass index (BMI) will be promoted to allow subgroup analyses and to explore potential associations between obesity and procedural complications, thus strengthening the external validity of the study. This demographic selection is justified by prevalence patterns reported in the literature and by the need to capture clinically relevant effect modifiers in real clinical environments.\n* The suspicion of facet joint pain will be based on a compatible axial clinical pattern and the absence of objective neurological deficit, considering that neither physical examination nor imaging tests provide sufficient specificity. Therefore, diagnostic confirmation will be performed functionally through ultrasound-guided medial branch diagnostic blocks, which are the most reliable tool for attributing pain to the facet joint. The dual innervation of each lumbar facet joint will be considered; thus, two adjacent levels will be blocked per joint (the medial branch at the affected level and the one immediately above).\n* Eligible patients will be those with a positive functional screening in two independent medial branch diagnostic blocks performed with anesthetics of different duration, in separate sessions, to reduce false positives.\n* The diagnosis will be confirmed in cases reporting clinically relevant pain relief within the expected pharmacological window.\n\nExclusion Criteria:\n\n* Exclusion criteria will include red flags or specific etiologies such as infection, neoplasm, fracture, or cauda equina syndrome, as well as patients with progressive motor radiculopathy or another demonstrated neuropathic pain source other than facet origin.\n* Individuals who have undergone prior procedures that could compromise response interpretation such as recent radiofrequency denervation, cryoneurolysis or intra-articular corticosteroid injections within a period that could extend analgesic effects.","80 Years",{"count":659,"type":23},82,[633],"Chronic musculoskeletal pain of non-specific origin affects approximately 30% of the global population. Beyond its prevalence, it represents a serious health and socioeconomic problem. It is considered the leading cause of years lived with disability and is characterized by persistent functional limitation, deterioration of quality of life, and poorer mental health, with a high comorbidity of depression, anxiety, and sleep disorders, as well as a greater risk of suicidal ideation and behavior.\n\nFrom a socioeconomic perspective, chronic pain entails an impact of up to USD 635 billion annually just in United States (USA). In fact, spinal pain alone represents the condition with the highest direct costs (around USD 134.5 billion in USA) and additional indirect costs due to absenteeism and presenteeism, which impair productivity and work performance. These figures are expected to be substantially higher when considered at a global scale.\n\nOne of the main aggravating factors of this condition is that in up to 90% of patients experiencing pain there is no identifiable anatomopathological substrate that reliably explains the symptoms (non-specific pain). Radiological findings are extremely common in asymptomatic populations, and making diagnostic or therapeutic decisions based on such findings, promotes overdiagnosis and low-value clinical cascades. It is estimated that up to 50% of imaging requests and 60% of spinal surgeries6 are unnecessary or unjustified. For this reason, Clinical Practice Guidelines recommend prioritizing interventional diagnostic techniques based on functional criteria over the interpretation of radiological findings, as they allow for more sensitive and specific identification of nociceptive sources (with a recommendation grade I-II).\n\nIn this context, the motivation of the project is to study PENS as a non-pharmacological, safe, and transferable alternative to nerve blocks, reducing the risk of complications associated with the use of local anesthetics\u002Fcorticosteroids and large-gauge needles. According to recent systematic reviews and meta-analyses confirming immediate analgesic responses, PENS could be a feasible alternative that maintains functional diagnostic and therapeutic value with a generally mild adverse-event profile and lower cost.",[663,664],"Non-specific Low Back Pain (NSLBP)","Facet Joint Syndrome",[666,667,668,669,670,671,672,673,674],"musculoskeletal ultrasound imaging","health care cost-utility","safety and adverse events","randomized clinical trial","pain neuromodulation","diagnostic nerve blocks","percutaneous electrical nerve stimulation","facet joint syndrome","non-specific low back pain","2026-01-09",{"date":677,"type":40},"2026-01-13",{"date":134,"type":23},{"date":680,"type":23},"2029-08-31",{"name":46,"class":47},{"id":683,"slug":684,"hasResults":12,"nctId":685,"briefTitle":686,"officialTitle":687,"acronym":688,"eligibilityCriteria":689,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":690,"targetDuration":4,"studyType":24,"phases":691,"briefSummary":692,"conditions":693,"keywords":695,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":702,"startDateStruct":703,"completionDateStruct":705,"leadSponsor":707,"locationsCount":138},"100617207","passive-fit-of-implant-supported-complete-arch-prostheses-using-digital-workflows-100617207","NCT07315620","Passive Fit of Implant-Supported Complete-Arch Prostheses Using Digital Workflows","Evaluation of Passive Fit in Implant-Supported Complete-Arch Prostheses Using Three Digital Workflows, Including an Automated AI-Assisted Protocol: A Randomized Clinical Trial","MFS03-Pdental","Inclusion Criteria:\n\n1. Adults aged 18 years or older.\n2. Patients indicated for fixed implant-supported full-arch rehabilitation in the maxilla or mandible.\n3. Presence of clinically stable, osteointegrated titanium implants suitable for prosthetic rehabilitation.\n4. Absence of clinical or radiographic signs of peri-implant disease.\n5. Ability to understand the study procedures and provide written informed consent.\n6. Willingness and ability to attend all required clinical visits and evaluations.\n\nExclusion Criteria:\n\n1. Presence of peri-implant mucositis or peri-implantitis at the time of evaluation.\n2. Implant mobility or implant positioning that prevents proper prosthetic rehabilitation.\n3. Uncontrolled systemic medical conditions that could interfere with study participation or prosthetic treatment.\n4. Cognitive, psychological, or medical conditions that limit the ability to comply with study procedures.\n5. Inability to complete the required clinical evaluations or follow the study protocol, as judged by the investigator.",{"count":207,"type":23},[26],"The goal of this clinical trial is to evaluate and compare three digital workflows for the fabrication of definitive implant-supported full-arch prostheses in adult patients requiring fixed implant rehabilitation.\n\nThe main questions it aims to answer are:\n\n* Does an automated AI-assisted digital workflow improve the passive fit of definitive full-arch implant-supported prostheses compared with manual and splint-guided alignment workflows?\n* Are there differences in marginal, geometric, mechanical, and radiographic passivity among the three digital workflows? Researchers will compare manual CBCT-STL alignment, splint-guided alignment, and automated AI-assisted CBCT-STL alignment to see if the degree of digital workflow automation affects the passive fit of definitive full-arch implant-supported prostheses.\n\nParticipants will:\n\n* Be adults (18 years and older) indicated for fixed implant-supported full-arch rehabilitation.\n* Receive a definitive, screw-retained, full-arch implant-supported prosthesis fabricated using one of the three assigned digital workflows.\n* Undergo standardized clinical and radiographic assessments at the time of definitive prosthesis placement to evaluate prosthesis passive fit.",[694],"Prosthesis and Implant Dentistry",[696,697,698,699,700,701],"Implant-Supported Prosthesis","Full-Arch Rehabilitation","Passive Fit","Digital Workflow","Computer-Aided Design and Manufacturing (CAD\u002FCAM)","AI-Assisted Workflow",{"date":675,"type":40},{"date":704,"type":23},"2026-01-01",{"date":706,"type":23},"2027-03-01",{"name":46,"class":47},""]